Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 2/20 | 0.50 |
| ▸ | TTR | P02766 | 1/20 | 0.49 |
| ▸ | DPP4 | P27487 | 1/20 | 0.49 |
| ▸ | CA12 | O43570 | 1/20 | 0.46 |
| ▸ | CA1 | P00915 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
| ▸ | CA7 | P43166 | 1/20 | 0.46 |
| ▸ | CA9 | Q16790 | 1/20 | 0.46 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.46 |
| ▸ | ESR1 | P03372 | 3/20 | 0.46 |
| ▸ | MAOB | P27338 | 1/20 | 0.46 |
| ▸ | SNCA | P37840 | 1/20 | 0.46 |
| ▸ | APP | P05067 | 7/20 | 0.40 |
| ▸ | P4HB | P07237 | 1/20 | 0.40 |
| ▸ | FDPS | P14324 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4264960 | 1.00 | CYP3A4 (0.50) | CYP3A4TTRDPP4CA12CA1 | |
| SCHEMBL4259318 | 0.89 | CYP3A4 (0.49) | CYP3A4TTRDPP4CA12CA1 | |
| SCHEMBL4259312 | 0.89 | CYP3A4 (0.49) | CYP3A4TTRDPP4CA12CA1 | |
| SCHEMBL4255141 | 0.88 | TTR (0.49) | CYP3A4TTRDPP4CA12CA1 | |
| SCHEMBL4255135 | 0.88 | TTR (0.49) | CYP3A4TTRDPP4CA12CA1 | |
| SCHEMBL4259398 | 0.87 | CA12 (0.64) | CYP3A4TTRDPP4CA12CA1 | |
| SCHEMBL4259404 | 0.87 | CA12 (0.64) | CYP3A4TTRDPP4CA12CA1 | |
| SCHEMBL3468158 | 0.86 | SNCA (0.51) | CYP3A4TTRDPP4CA12CA1 | |
| SCHEMBL3468156 | 0.86 | SNCA (0.51) | CYP3A4TTRDPP4CA12CA1 | |
| SCHEMBL4253230 | 0.85 | CYP3A4 (0.53) | CYP3A4TTRDPP4CA12CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7569601-B2 | Cycloalkylidene compounds as modulators of estrogen receptor | SMITHKLINE BEECHAM CORPORATION (US) | 2009-08-04 | — | — | US | disclosed |
| US-20070213348-A1 | Chemical Compounds | BRITTON JONATHAN E | 2007-09-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070213348-A1 | Chemical Compounds | GPER1, ESR2, ESR1 | CYP3A4 428/4885TTR 4866/4885DPP4 1371/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.